PRX-MET

N/A

Report date: 2025/05/14 13:52:06

Base Information

Drug NamePRX-MET

Drug Alias NameMET Inhibitors (PhaseRx)PRX-MET

ClassificationCell and gene therapy > Gene therapy > mRNASmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA

Mechanisms of ActionHepatocyte growth factor receptor inhibitors

TargetsHepatocyte growth factor receptor

Therapy Area/IndicationsCarcinoma, Hepatocellular

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesPhaseRx Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesPhaseRx Inc

Active IndicationsN/A

Inactive IndicationsCarcinoma, Hepatocellular

Other Information

ATC CodeN/A